Amplification of AKT1 and a somatic mutation of AKT2 have been previously reported in GC, and about 80% of tumors have been found to have elevated levels of Akt and phosphorylated Akt, which showed a statistically significant correlation with poor patient outcomes in GC (21). This evidence concerns the gene AKT2 and gastric cancer.